Tomoyuki Hishida1, Shogo Nomura2, Motoki Yano3, Hisao Asamura4, Motohiro Yamashita5, Yasuhisa Ohde6, Keishi Kondo7, Hiroshi Date8, Meinoshin Okumura9, Kanji Nagai10. 1. Department of Thoracic Surgery, National Cancer Centre Hospital East, Chiba, Japan thishida@nifty.com. 2. Center for Research Administration and Support, National Cancer Centre, Chiba, Japan. 3. Department of Oncology, Immunology and Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. 4. Department of Thoracic Surgery, National Cancer Centre Hospital, Tokyo, Japan Present address: Division of Thoracic Surgery, Keio University School of Medicine, Tokyo, Japan. 5. Department of Thoracic Surgery, Shikoku Cancer Centre, Ehime, Japan. 6. Division of Thoracic Surgery, Shizuoka Cancer Centre, Shizuoka, Japan. 7. Department of Thoracic Surgery, Hokkaido Cancer Centre, Sapporo, Japan. 8. Department of Thoracic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan. 9. Department of Thoracic Surgery, Osaka University Graduate School of Medicine, Osaka, Japan. 10. Department of Thoracic Surgery, National Cancer Centre Hospital East, Chiba, Japan.
Abstract
OBJECTIVES: Thymic carcinoma is a rare thymic malignancy. The purpose of this study was to evaluate the prognostic impact of clinicopathological variables and perioperative therapy for surgically treated thymic carcinoma using a nationwide database. METHODS: Of 2835 patients with surgically treated thymic epithelial tumours collected from 32 Japanese institutions, a total of 306 patients with thymic carcinomas, excluding neuroendocrine tumours, were enrolled in this retrospective study. Multivariable Cox regression analyses were performed for overall (OS) and recurrence-free survival (RFS) after R0 resection. RESULTS: Of 306 patients, 228 (75%) patients presented with Masaoka stage III-IV. Squamous cell carcinoma was the most common histological type (n = 216, 71%). R0 resection was performed in 181 (61%) patients, R1 in 46 (16%), R2 sub-total (≥80% tumour resection) in 43 (14%) and R2 non-resection in 27 (9%). The 5-year OS rate was 61%. Prognostic factors for OS were Masaoka stage and resection status. R0 resection was associated with most improved OS; however, both R1 and R2 sub-total resection resulted in superior OS compared with R2 non-resection [hazard ratio (95% confidence interval) for R0, R1 and R2 sub-total, 0.27 (0.15-0.48), 0.40 (0.22-0.74) and 0.38 (0.20-0.72), respectively]. Histological type and perioperative therapy did not affect OS, whereas tumour size and postoperative radiotherapy were associated with improved RFS after R0 resection. CONCLUSIONS: R0 resection is essential for prolonged OS for surgically treated thymic carcinoma, but maximal debulking surgery might be beneficial and worth evaluating for advanced disease deemed difficult for R0 resection. The benefit of postoperative radiotherapy after R0 resection should also be evaluated prospectively.
OBJECTIVES:Thymic carcinoma is a rare thymic malignancy. The purpose of this study was to evaluate the prognostic impact of clinicopathological variables and perioperative therapy for surgically treated thymic carcinoma using a nationwide database. METHODS: Of 2835 patients with surgically treated thymic epithelial tumours collected from 32 Japanese institutions, a total of 306 patients with thymic carcinomas, excluding neuroendocrine tumours, were enrolled in this retrospective study. Multivariable Cox regression analyses were performed for overall (OS) and recurrence-free survival (RFS) after R0 resection. RESULTS: Of 306 patients, 228 (75%) patients presented with Masaoka stage III-IV. Squamous cell carcinoma was the most common histological type (n = 216, 71%). R0 resection was performed in 181 (61%) patients, R1 in 46 (16%), R2 sub-total (≥80% tumour resection) in 43 (14%) and R2 non-resection in 27 (9%). The 5-year OS rate was 61%. Prognostic factors for OS were Masaoka stage and resection status. R0 resection was associated with most improved OS; however, both R1 and R2 sub-total resection resulted in superior OS compared with R2 non-resection [hazard ratio (95% confidence interval) for R0, R1 and R2 sub-total, 0.27 (0.15-0.48), 0.40 (0.22-0.74) and 0.38 (0.20-0.72), respectively]. Histological type and perioperative therapy did not affect OS, whereas tumour size and postoperative radiotherapy were associated with improved RFS after R0 resection. CONCLUSIONS: R0 resection is essential for prolonged OS for surgically treated thymic carcinoma, but maximal debulking surgery might be beneficial and worth evaluating for advanced disease deemed difficult for R0 resection. The benefit of postoperative radiotherapy after R0 resection should also be evaluated prospectively.
Authors: Annemarie Shepherd; Gregory Riely; Frank Detterbeck; Charles B Simone; Usman Ahmad; James Huang; Robert Korst; Arun Rajan; Andreas Rimner Journal: J Thorac Oncol Date: 2016-11-19 Impact factor: 15.609
Authors: Sara A Hayes; James Huang; Jennifer Golia Pernicka; Jane Cunningham; Junting Zheng; Chaya S Moskowitz; Michelle S Ginsberg Journal: Ann Thorac Surg Date: 2018-03-11 Impact factor: 4.330
Authors: Jose Arimateia Batista Araujo-Filho; Maria Mayoral; Junting Zheng; Kay See Tan; Peter Gibbs; Annemarie Fernandes Shepherd; Andreas Rimner; Charles B Simone; Gregory Riely; James Huang; Michelle S Ginsberg Journal: Ann Thorac Surg Date: 2021-04-09 Impact factor: 5.102
Authors: Giye Choe; Amanda Ghanie; Gregory Riely; Andreas Rimner; Bernard J Park; Manjit S Bains; Valerie W Rusch; Prasad S Adusumilli; Robert J Downey; David R Jones; James Huang Journal: J Thorac Cardiovasc Surg Date: 2019-09-13 Impact factor: 5.209